MedTrace Logo

Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia

NCT04528927 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2020-08-27

No results posted yet for this study

Summary

Evaluation of the efficacy and safety of Treatments for Patients Hospitalized for COVID-19 Infection without signs of acute respiratory failure, in Tunisia Multicentric Randomized Comparative Study

Conditions

  • COVID 19
  • Patients Hospitalized

Interventions

DRUG

HCQ

600 mg on the 1st day as a starting dose then 200 mg \* 2 /D for 9 days

DRUG

Azithromycin

500 mg (1st day) then 250 mg / D for 4 days

DRUG

Doxycycline

200 mg per day for 10 days

DIETARY_SUPPLEMENT

Zinc

220 mg per day for 10 days

Sponsors & Collaborators

  • Eshmoun Clinical Research Center

    collaborator NETWORK

  • Datametrix

    collaborator INDUSTRY

  • Abderrahmane Mami Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-15
Primary Completion
2020-07-15
Completion
2020-07-15

Countries

  • Tunisia

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04528927 on ClinicalTrials.gov